Results Press Release for June 30, 2016
Marksans Pharma Ltd has informed BSE about : 1. Result Press Release for the period ended June 30, 201613-08-2016
13-08-2016
Standalone & Consolidated Financial Results, Limited Review Report for June 30, 2016
Marksans Pharma Ltd has informed BSE about : 1. Standalone Financial Results for the period ended June 30, 20162. Consolidated Financial Results for the period ended June 30, 20163. Standalone Limited Review for the period ended June 30, 201613-08-2016
Board Meeting Intimation for Results
Marksans Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company will be held on August 13, 2016, inter alia, to consider and approve Unaudited Financial Results of the Company for the Quarter ended on June 30, 2016.05-08-2016
Shareholding for the Period Ended June 30, 2016
Marksans Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2016. For more details, kindly Click here19-07-2016
Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended June 30, 2016
Marksans Pharma Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended June 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.19-07-2016
Results Press Release for March 31, 2016
Marksans Pharma Ltd has informed BSE about : 1. Result Press Release for the period ended March 31, 201630-05-2016
Standalone & Consolidated Financial Results, Auditors Report for March 31, 2016
Marksans Pharma Ltd has informed BSE about : 1. Standalone Financial Results for the period ended March 31, 20162. Consolidated Financial Results for the period ended March 31, 20163. Standalone Auditors Report for the period ended March 31, 20164. Consolidated Auditors Report for the period ended March 31, 20165. Declaration regarding Audit Report with unmodified opinion30-05-2016
Board recommends Dividend
Marksans Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 30, 2016, has recommended dividend of Rs. 0.12 (Rupees Zero and Paise Twelve) i.e. 12% per equity share of Re. 1/- each face value for the financial year ended March 31, 2016, subject to approval of the shareholders in the ensuing Annual General Meeting.30-05-2016
Board to consider Dividend
Marksans Pharma Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 30, 2016, inter alia, to consider and approve Audited Financial Results of the Company for the financial year ended March 31, 2016 and to consider recommendation of dividend, if any, for the financial year ended March 31, 2016.20-05-2016